Market Research Report
Global Infectious Disease Therapeutics Market 2019-2023
|Published by||TechNavio (Infiniti Research Ltd.)||Product code||762834|
|Published||Content info||120 Pages
Delivery time: 1-2 business days
|Global Infectious Disease Therapeutics Market 2019-2023|
|Published: December 12, 2018||Content info: 120 Pages||
Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. Technavio's analysts have predicted that the infectious disease therapeutics market will register a CAGR of over 4% by 2023.
There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.
Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.
For the detailed list of factors that will drive and challenge the growth of the infectious disease therapeutics market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Merck and Sanofi the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures. AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.